Details of the Drug Combination

General Information of Drug Combination (ID: DCY7GDV)

Drug Combination Name

Terameprocol Aminolevulinic Acid Hydrochloride

Indication

Disease Entry	Status	REF
Minimally invasive lung adenocarcinoma	Investigative	[1]

Component Drugs

Terameprocol DMC3P45

Aminolevulinic Acid Hydrochloride DMWNHPC

Small molecular drug

2D MOL

3D MOL

3D MOL is unavailable

High-throughput Screening Result

Testing Cell Line: NCI-H322M

Zero Interaction Potency (ZIP) Score: 0.57

Bliss Independence Score: 3.59

Loewe Additivity Score: 1.8

LHighest Single Agent (HSA) Score: 1.59

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of Terameprocol

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 2	[2]

Terameprocol Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Transcription factor Sp1 (SP1)	TTZEP6S	SP1_HUMAN	Modulator	[2]
------------------------------------------------------------------------------------

Indication(s) of Aminolevulinic Acid Hydrochloride

Disease Entry	ICD 11	Status	REF
Actinic keratosis	EK90.0	Approved	[3]

Aminolevulinic Acid Hydrochloride Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Protoporphyrinogen oxidase (PPOX)	TTNFMS9	PPOX_HUMAN	Modulator	[4]
------------------------------------------------------------------------------------

References

1	Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2	Terameprocol, a novel site-specific transcription inhibitor with anticancer activity. IDrugs. 2008 Mar;11(3):204-14.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.